🇺🇸 biphasic insulin aspart in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Lactic Acidosis — 2 reports (18.18%)
- Abdominal Pain Upper — 1 report (9.09%)
- Bacterial Test Positive — 1 report (9.09%)
- Bronchial Obstruction — 1 report (9.09%)
- Carotid Artery Stenosis — 1 report (9.09%)
- Chest Pain — 1 report (9.09%)
- Culture Urine Positive — 1 report (9.09%)
- Cytolytic Hepatitis — 1 report (9.09%)
- Diabetic Ketoacidosis — 1 report (9.09%)
- Hyperkalaemia — 1 report (9.09%)
Other Diabetes approved in United States
Frequently asked questions
Is biphasic insulin aspart approved in United States?
biphasic insulin aspart does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for biphasic insulin aspart in United States?
Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.